Financings, debt, distress, legal cases, listing changes and mergers at public medical device and diagnostics companies, newest first. Every story links its primary source.
Listings ·
Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026.
GCTKThe Capitol dome against a blue sky. Photo: Carol M Highsmith, CC0, via rawpixel
Debt Financing
The amendment lowers a prepayment figure and three investment baskets from $500,000 to $250,000 and requires Required Lenders consent for certain acquisitions and equity redemptions. JPMorgan Chase Bank, N.A. is administrative agent.
SNWV
Listings
OSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing.
OSRH
Company Updates
The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy.
LFWDICCM
Debt Financing
The remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more.
VNRXA purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable.
BBNXBank of America, N.A. is administrative agent under the new unsecured credit agreement. The company repaid $130.0 million under its 2019 credit agreement.
WSTThe 2023 Pembroke Pines suit over FDA findings at the Boston plant is still being contested after a supplemental amended complaint. Two derivative suits are stayed behind it.
IARTThe company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027.
GUTSThe split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27.
NUWEThe senior secured convertible notes carry a 22% original issue discount, 8% interest and a 9-month term. Dawson James Securities, Inc. is named as placement agent.
GCTKMatt Aune resigned as chief financial officer on October 19, 2026, and the board named Sandra J. Bonar interim principal financial officer effective October 20, 2026.
PREMThe offering totals $40,000,000 at the public offering price, with $37,600,000 to Teknova before expenses. Underwriters have a 30-day option to buy up to 1,200,000 more shares.
TKNOIntegra refinanced a $1.3 billion revolver and a $775 million term loan with $450 million of 9.500% notes due 2033 and a $1.65 billion credit agreement, after reporting a 2025 net loss of $516.5 million.
IARTPatients kept about 80% of their tirzepatide weight loss after one Revita procedure versus 67% after sham. Fractyl plans a De Novo filing in late fourth quarter 2026.
GUTSThe investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement.
TNONThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
MDXGThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
MDXGThe note carries 7% interest, converts at $4.28 a share and matures in October 2027.
PFSAUnder an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option.
OSRHThe preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.
IDXGBluejay Diagnostics said it finished establishing a Symphony cartridge manufacturing site under its amended Toray license, ahead of an October 23, 2026 deadline.
BJDXThe merger with Langham Merger Sub took effect on October 13, 2026, and LogicMark is now a wholly owned subsidiary of Langham Project LLC.
LGMKThe 9.500% notes are due 2033 and will help refinance the company's existing credit facilities.
IARTGrowth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price.
SSIIThe note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027.
CODXJ.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital.
CODXThe licence is payable in BioNexus shares, and closing remains subject to technology delivery and approvals.
BGLCEvery 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP.
NXGLAtlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants.
COCHA federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending.
NEOGThe preliminary analysis covers 777 evaluable patients with an overall 28-day mortality rate of approximately 18%. The company says the baseline data do not yet establish the test's performance.
BJDXWells takes the role effective October 1, 2026 under a services agreement with Atlas Bookkeeping, LLC, and becomes the company's principal financial and accounting officer.
GIPLThe board replaced an expiring rights agreement with one meant to protect net operating loss carryforwards, with rights tied to holders of record on October 13, 2026.
SNOAThe company did not cure asserted defaults, returned two Citation CJ3 aircraft on October 1, 2026, and lessors claim approximately $514,557 under the leases.
PREMDirector Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028.
AURXHolders exercised older warrants at a reduced $3.866 per share and received new warrants. H.C. Wainwright & Co., LLC acted as exclusive placement agent, and the offering closed on October 5, 2026.
ICUAscent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.
PFSADefendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit.
LNTHA holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.
ADGMThe October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.
NDRAAt an October 1, 2026 virtual annual meeting, stockholders also approved 100,000 more shares for the equity plan and 20,000,000 authorized preferred shares.
AEMDThe cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan.
SGP4536BLCODr. Constance Hoefer gave notice on September 30, 2026, and her resignation took effect at once, the company reported in an 8-K filed October 2.
OSRHBeijing Rural Commercial Bank is the lender. A director gave an unsecured personal guarantee for the loan without consideration, and the company held $779,367 in cash and cash equivalents at June 30, 2026.
ITOCThe notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share.
POSCNutriband's public warrants expired on September 30 without extension or repricing. Nasdaq filed a Form 25 to remove them. The company said its common stock is not affected.
NTRBTwo notes held by LGH Investments, LLC and Peter J. D'Arruda now mature on January 31, 2027. All other terms stay the same, the filing says.
ODYYCuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager.
CUPRThe consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent.
TELAThe amendment makes the floor price a hard limit and requires any make-whole payment to be made in cash. Glucotrack had $1.1 million in cash and cash equivalents at June 30, 2026.
GCTKAdvanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that.
ADVBPolyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months.
PLRZThe board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable.
ADGMIn a strategic update dated September 23, 2026, Glucotrack and Lokahi Therapeutics said LT-100 is the immediate priority, with a clinical protocol submitted for regulatory review.
GCTKThe amendment extends the term loan maturity by one year, to the 72nd payment date after closing. PROCEPT BioRobotics paid a $26,000.00 extension fee.
PRCTBank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026.
QDELMorgan Stanley Senior Funding, Inc. is administrative agent. The margin on the refinanced term loans falls 0.25%, and cash and cash equivalents were $534.9 million at June 30, 2026, down from $716.1 million at the end of 2025.
PODDThe deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027.
AEMDThe companies will test whether ReadyGo's sample-preparation technology can work with the Co-Dx PCR platform on blood samples. Compatibility has not yet been established.
CODXAscent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.
PFSANasdaq says the closing bid has been below $1 for 30 consecutive business days. The company completed a 1-for-6 reverse split in June 2025 and plans to seek approval for another at its next annual meeting.
BBLGA purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable.
BBNXDirector Paul V. Goode resigned effective immediately after notifying the board on September 14, 2026, saying the merger agreement with Lokahi Therapeutics, Inc. could create a conflict of interest between the company and its subsidiary.
GCTKHolders exercised 572,179 existing warrants for cash and received new warrants for 858,269 shares at $5.02 per share. WallachBeth Capital acted as financial advisor, and the closing was expected on or about September 14, 2026.
TNONThe nine-month notes carry 8% interest and a 22% original issue discount, with Dawson James Securities, Inc. as placement agent and an exchange cap of 19.99%.
GCTKRegentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026.
RGNTCerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028.
CNSYTenon repaid in full original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, issued March 11, 2026. The release names no noteholder or agent.
TNONA September 2026 investor presentation filed as Exhibit 99.1 sets out the company's product timeline, its Oramed-linked oral delivery program and its reported cash and revenue.
LFWDLovell will be Bluejay's exclusive distributor for federal procurement opportunities that favor veteran-owned small businesses, once its products receive FDA clearance or other required authorization.
BJDXThe advisor will introduce investors and strategic partners for transactions the company approves, under an agreement effective August 24, 2026.
STMEIntellia Therapeutics will receive $75 million at closing under the facility. Up to $225 million more depends mainly on milestones for lonvo-z.
NTLANutriband says its operations will fund the next year and that going-concern doubt is gone, but revenue and spending both fell in the quarter and the company still burned cash.
NTRBJoseph Gunnar and Lucosky Brookman sued Nutriband, CEO Gareth Sheridan, President Serguei Melnik, Vitalie Botgros, TII Jet Services and Wolf Blitz in 2023 over a terminated offering engagement. Nutriband denies the claims and has counterclaimed.
NTRBPolyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion.
PLRZLind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026.
VNRXThe private placement brings about $5.0 million at closing, with a further $5 million tranche of warrants, and Ladenburg Thalmann & Co. Inc. acts as placement agent.
INBSThe note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser.
PFSAMark Grant leaves as president, chief executive and director effective August 31, 2026, and Josh Hexter becomes interim chief executive on September 1. Rami Aviram is named chief financial officer effective November 1, 2026.
LFWDTenon Medical agreed to sell 597,610 shares, or pre-funded warrants, to an institutional investor, with warrants for up to 1,058,517 more shares. WallachBeth Capital LLC is the exclusive placement agent.
TNONThe reverse split took effect August 28, 2026, with trading on a split-adjusted basis from August 31, 2026, and shares outstanding were reduced from 11,972,157 to approximately 798,144.
GCTKEach 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol.
FEEDThe Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing.
OSRHThe August 2026 deck says first-half revenue rose 20% and that cash runway extends through 2Q27.
NUWEThe split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.
IDXGBrian Kieser became interim chief executive on August 21, 2026, as Adam Levy left the role. A special committee will review non-core assets, liquidity and the company's long-term strategic direction.
NXGLThe unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC.
NXLAfter raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity.
BDXProfusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.
PFSANasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026.
OSRHRevenue rose 38% and gross margin reached 48.63%, and the company says its FDA 510(k) submission remains on track for the second half of calendar 2026.
INBSHolders tendered $756,712,000 of the 2.539% notes due 2032 by the early tender time. The offer cap rose from $500 million to $600 million.
BAXENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026.
NDRAASPIThe company reported stockholders' equity of negative $415,000 at June 30, 2026, below Nasdaq's $2,500,000 minimum, and must submit a compliance plan by September 28, 2026.
ADGMNet sales fell from $10.4 million a year earlier, and the quarter's net income of $2.8 million includes a $6.4 million gain on the sale of equity securities.
RVPLifeward reported a net loss of $11.5 million for the quarter and said a July 6, 2026 financing could provide up to $11.2 million in growth capital.
LFWDLucid Diagnostics recognized $1.5 million in EsoGuard revenue in the second quarter, and PAVmed reported cash of $3.8 million at June 30, 2026.
PAVMLUCDRevenue for the three months ended June 30, 2026 was $418,264, a decrease of 16% from the 2025 period. The company said most of the decline came from international markets.
VYCOThe amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million.
TRIBNet sales were $2.0 million in the quarter, and the company says recent financings extend its cash runway through the second quarter of 2027.
NUWEThe company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.
BJDXRevenue rose 127% from a year earlier and gross margin reached 64%. Cash was $1.7 million at June 30, 2026, before a $4.2 million offering that closed on July 1.
TNONThe net loss was $6.3 million, or $1.46 per share, and cash and cash equivalents were $3.6 million at June 30, 2026. The company said it submitted a 510(k) for its flu A/B and RSV test.
CODXThe company reported cash of approximately $4.9 million at June 30, 2026, after raising about $4.0 million in gross proceeds after quarter-end, and operating expenses down 11.9%.
AEMDThe note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues.
POSCThe company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor.
FEEDThe note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor.
PFSARevenue was $9.1 million, down slightly from the prior-year quarter as reported, while income from continuing operations was $0.3 million and thyroid revenue rose 9%.
IDXGThe company said a July 31 statement should not be read as Nasdaq approval of the Shareholder Loyalty CVR Program, and the August 14, 2026 record date is unchanged.
OSRHGlucotrack amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, agreeing to issue 2,505,513 commitment shares and to pay a true-up amount if the commitment fee price falls below the minimum price.
GCTKA jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit.
NTRAAn April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.
CLDXSecond-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.
SGPGKOSA Massachusetts court fully granted dismissal of the Gonzalez suit against Intellia (Nasdaq: NTLA) and unnamed officers on June 18, 2026. A Delaware suit against directors and BlueAllele's patent suit remain open.
NTLAGlucotrack issued follow-on senior secured convertible notes with a $4,487,179 face amount and sold pre-funded warrants in an interim private placement.
GCTKThe agreement dated July 31, 2026 would convert LogicMark into a wholly owned subsidiary of Langham Project, LLC, subject to a shareholder vote and other conditions.
LGMKTotal revenue rose 40.1% to $847,490 in the quarter ended June 30, 2026, and ISP revenue rose 86.4%, the company said in unaudited results.
USAQLadenburg Thalmann & Co. Inc. is the exclusive placement agent, and the deal includes warrants to buy up to 1,310,890 shares.
NUWEIn a verbal communication, Nasdaq said the Shareholder Loyalty CVR program will not trigger a mechanical price adjustment, OSR Health said on July 31, 2026.
OSRHHolders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.
CODXThe split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.
AEMDSuits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida.
BAXLinet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open.
BAXLokahi Therapeutics, a wholly owned subsidiary of Glucotrack, said nonclinical results support testing one subcutaneous injection in place of up to 15 intradermal injections, with clinical evaluation possibly starting in the fourth quarter of 2026.
GCTKAccuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval.
ARAYA third amendment to the credit agreement with Fifth Third Bank, National Association, sets a standstill period that runs to June 30, 2027.
AMSAfter a working visit to China, BioNexus says it is preparing the VitaGuard platform for ten licensed Southeast Asian markets.
BGLCProfusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount.
PFSAA single healthcare-focused institutional investor bought the shares. The company says the financing extends its runway through Q2 2027, and warrants could add up to about $6.0 million more if exercised for cash.
BBLGThe July 23, 2026 agreement sets a $375,000 base salary, EBITDA-linked bonus tiers and an option grant of 160,000 shares at $0.647 per share.
NXGLThe amended agreement sets a maximum price of $21,306,000 for companies bought from seller Gary C. Bernard, M.D., and it depends on a related business combination that has not closed.
FCHSPreliminary observations show an approximately 17% 28-day mortality rate in the enrolled population. The company expects to complete data cleaning, statistical analysis and clinical reporting over the coming months.
BJDXAnika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets.
ANIKKestra Medical drew $75.0 million from a facility of up to $200.0 million. The Tranche A loan funded on July 10, 2026, and repaid a prior loan from Perceptive Credit Holdings IV, LP.
KMTSNasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.
NDRABone Biologics sold pre-funded warrants for 2,112,677 shares at a combined $1.419 each, with Series F and G warrants at $1.42, through H.C. Wainwright & Co. Net proceeds were about $2.7 million, and the 10-K carries a going-concern warning.
BBLGMaxim Group LLC is sole placement agent for 5,633,009 shares or pre-funded warrants, each sold with a warrant for the same number of shares.
AEMDAspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan.
AWHLThe notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher.
LFWDThe offering is priced at $0.38 per share and common warrants. WallachBeth Capital LLC is the sole placement agent, and part of the proceeds will repay convertible notes.
TNONShoulder Innovations signed a $15.0 million senior secured term loan with Stifel Bank on June 26, 2026, and used it to repay Trinity Capital. The $30.0 million asset-based revolver was undrawn at closing.
SIThe split takes effect at 5:00 p.m. Eastern Time on June 25, 2026, and NUWE shares trade split-adjusted from June 26.
NUWEA prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703.
SNOAChairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final.
AWHLJohn Erb steps back from the executive role and remains Chairman of the Board, and the new chief executive takes over on June 30, 2026.
NUWEThe June 2026 letter reports an eight-month heartworm study begun April 1, 2026, a FINRA application submitted June 12, 2026, and a collaboration paying approximately $15,000 to $18,000 a month.
GIPLThe company's common stock traded below $1.00 for 30 consecutive business days, and it has 180 calendar days to regain compliance.
ADGMCuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million.
CUPRAethlon Medical reported a net loss of $7.2 million for the fiscal year ended March 31, 2026, and said its Australian oncology study has entered its third and final dosing cohort.
AEMDBioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.
BRTXNUWEISPCStockholders approved a reverse split at a fixed ratio between 1-for-2 and 1-for-20, but the board has no present intention to carry it out in the next 12 months.
BJDXLadenburg Thalmann & Co. Inc. was sole book-running manager, and the deal included Series C warrants for up to 60,000,000 shares.
NUWEVivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed.
VVOSCelcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day.
CELCThe June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent.
AWHLThe board postponed the annual stockholder meeting that had been scheduled for June 18, 2026, and said it has not yet set a new date.
OSRHCerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%.
CERSCONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show.
CNMDCelcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan.
CELCThe notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42.
CELCThe strategic partnership with Argonaut Manufacturing Services aims to build U.S.-based manufacturing for the Symphony platform and reduce reliance on overseas sourcing.
BJDXCity National Bank of Florida will lend up to $15,000,000 under a revolving note that matures June 5, 2027.
SRTSTeleflex will use the proceeds, with cash on hand, to redeem its outstanding 4.625% Senior Notes due 2027. The notes are being sold in a private offering.
TFXNutriband amended its $5 million credit line with TII Jet Services, a lender in Portugal. Advances carry 7% interest and may be used only for work with Kindeva toward the fentanyl NDA.
NTRBFifth Third Bank's May 29, 2026 notice cites four specified events of default under the credit agreement and raises the interest rate to the default rate.
AMSFive lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028.
AURXENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC.
NDRAMedline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets.
MDLNThe $30,000,000 price is due in full on completion of a Phase 2 study of VXM01, and the company may make voluntary partial payments before then.
OSRHThe credit agreement names JPMorgan Chase Bank, N.A. as administrative agent. The company's Form 8-K describes a revolver and two term loan facilities that refinance its earlier agreement.
TFXThe first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent.
CNMDSINTX Technologies received a Nasdaq notice on May 22, 2026 that its stockholders' equity, about $904,000 at March 31, 2026, is below the $2.5 million minimum. It has until July 6, 2026 to submit a plan to regain compliance, and its 2025 annual report carries a going-concern paragraph.
SINTThe master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms.
AWHLDefendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.
SGPGKOSNet sales fell from $8.3 million a year earlier, the operating loss widened to $6.2 million, and the company cut its workforce by approximately 16% in April.
RVPPAVmed ended the first quarter with $6.5 million in cash, and Lucid Diagnostics' underwritten offering netted about $17 million.
PAVMRevenue for the three months ended March 31, 2026 was $458,540, an increase of $22,162, or 5%, over the 2025 period. The company said most of the growth came from international markets.
VYCOWarrant holders paid approximately $1,963,967 in gross proceeds on May 12, 2026 under an incentive program. The company also raised its stockholder meeting quorum to one-third to match Nasdaq rules.
CNXUThe net loss was $9.1 million, or $4.06 per share, and cash and cash equivalents were $8.2 million at March 31, 2026. The company said enrollment in its upper respiratory test studies is complete.
CODXCuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting.
CUPRRevenue reached $3.2 million and gross margin 69.6%, while the operating loss narrowed to $1.5 million and cash and investments totaled $7.5 million.
LGMKTotal revenue reached $1.06 million for the quarter ended March 31, 2026, and nine-month revenue reached $3.07 million, up 39% year over year.
INBSA $30.1 million gain on warrant liabilities turned a $20.8 million operating loss into $9.2 million of net income.
GUTSNet sales were $2.4 million, and the company reported about $2.2 million of cash and no debt at March 31, 2026.
NUWERevenue was $9.0 million, down 22% from the prior-year quarter as reported and up 14% on a pro forma basis, and the company reaffirmed its 2026 thyroid growth guidance.
IDXGThe unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing.
NXGLThe prospectus registers resale shares only, so the company gets no proceeds from those sales. It expects Nasdaq trading on or about May 21, 2026, and its own financials carry going-concern doubt.
CNXUFirst-quarter cash was $451.5 million before the April offering. Celldex then expected phase 3 hives data in the fourth quarter of 2026.
CLDXAbout 680 patients were enrolled in SYMON-II as of May 5, 2026, toward a target of 750, and the company reported a first-quarter net loss of approximately $1.9 million.
BJDXOragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.
OGENSIGYJPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements.
ATECRegentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close.
RGNTBCM Europe, the company's largest shareholder, holds an exclusive global license and has pledged its entire stake as collateral for milestone payments of up to $815 million.
OSRHIntellia filed to sell $150 million of common stock on April 27, 2026 and priced 16,744,187 shares at $10.75 on April 28. Its preliminary cash at March 31 was $517.2 million, and its risk factors say the FDA has lifted a clinical hold on the nex-z Phase 3 trials.
NTLAJohn Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended.
AWHLAchieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026.
ACHVCaris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025.
CAIRenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026.
RNXTRegentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling.
RGNTNutriband said its board ended the deal after the buyer missed the December 31 closing and stopped paying late fees. The annual report puts the price at $5 million, and only $30,000 in late fees was received.
NTRBSpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials.
SGPVivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash.
VANIBausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash.
BLCONatera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones.
NTRAExpected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.
PLRZBaxter closed a three-series senior notes offering on December 4, 2025 and used part of the proceeds to repay its term loan. The rest is earmarked for cash tender offers on older notes, so the company is swapping debt rather than shrinking it.
BAXPolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has.
PYPDAdvanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished.
ADVBQ/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning.
QCLSElutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027.
ELUTBSXUnder a September 14, 2025 inducement agreement, a holder exercised 600,000 series H options and received 600,000 series J options. A separate exercise of 374,167 options produced gross proceeds of approximately $896,000.
MBOTFractyl is selling 60,000,000 shares through BofA Securities, Evercore ISI and Ladenburg Thalmann, after a $1.05 raise in August. The prospectus supplement carries going-concern language.
GUTSThe former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised.
QCLSA second closing should add about $4 million. New series J options could bring about $63 million more if fully exercised.
MBOTCelcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones.
CELCThe company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now.
OSRHBone Biologics says its June offering raised $5 million gross and that it expects cash to fund operations into the second quarter of 2026, while enrollment in its pilot study is slower than planned.
BBLGPrivate investors exercised warrants for 778,041 shares and public holders for 47,076 shares. Employee options added $44,206.
NTRBNasdaq said Envoy did not regain compliance with its $35,000,000 market value of listed securities requirement. A hearing request filed August 29, 2025 stays any trading suspension.
COCHNasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025.
CNSYSigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date.
SIGYTNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers.
QCLSVivani's Share Purchase Agreement with an entity affiliated with a director and another investor is expected to close in stages through July 15, 2026. The company says the proceeds secure its financial position into the second half of 2026.
VANIVivani sells 7,936,507 shares at $1.26 to two buyers, one of them tied to chairman Gregg Williams. Cash was $8.1 million at June 30, 2025, and the release presents the new money as securing its position into the second half of 2026.
VANIHolders got one non-voting preferred share for every four common shares. The shares convert one-for-one only after FDA approval of an AVERSA-based product.
NTRBCelcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering.
CELCThe stock closed below $1.00 for 32 consecutive business days. Shares keep trading on the Nasdaq Capital Market under ADVB during the compliance period.
ADVBLantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq.
LNTHThe notes mature January 15, 2031 and pay three-month EURIBOR plus 3.875%. The company also arranged a $2.325 billion term loan and an $800 million revolver, using the proceeds to repay and refinance existing debt.
BLCOAchieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning.
ACHVNasdaq says Bone Biologics has met the $1.00 bid price rule after a 10-day run, but the release gives no share price, and its lead product still needs FDA approval before sale.
BBLGInvestors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months.
CNSYHolders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.
PYPDIntegra LifeSciences' June 6, 2025 amendment lifts its maximum consolidated total leverage ratio to 5.00 to 1.00 through June 30, 2026, then steps it down. The company says total indebtedness does not rise, but the amendment also restricts investments, new borrowing and transfers of intellectual property until the relief period ends.
IARTNasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025.
CNSYThe company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025.
CNSYAspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment.
AWHLThe company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity.
CNSYThe company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination.
OSRHThe company says it is still compiling required information for its annual report for the year ended December 31, 2024.
NYMXFTriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change.
TLSIThe Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period.
CUPRNasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH.
AWHLNeogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms.
NEOGLantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible.
LNTHRenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period.
RNXTRenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.
RNXTTriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million.
TLSIThe company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date.
TLSINasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market.
QCLSTNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days.
QCLSAnika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles.
ANIKThe deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.
ANIKNasdaq says the market value of Envoy Medical's listed securities did not meet the minimum for 31 consecutive business days. The company has until August 25, 2025 to regain compliance.
COCHSINTX (Nasdaq: SINT) sold shares, pre-funded warrants and warrants for gross proceeds of $5.0 million before fees. H.C. Wainwright & Co. was placement agent, and the company will use net proceeds for working capital.
SINTThe Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years.
TLSIMicrobot Medical agreed to sell 6,103,289 shares at $2.13 in a registered direct offering, with unregistered warrants for up to 12,206,578 more shares. H.C. Wainwright & Co., LLC is the exclusive placement agent, and the company pays it a 7.0% cash fee.
MBOTRenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph.
RNXTBaxter completed the sale of its Kidney Care business on January 31, 2025 and received about $3.71 billion in net, pre-tax cash at closing, against a $3.80 billion price set at signing. The price is still subject to post-closing adjustments, and executive Chris Toth stepped down on the closing date.
BAXBeta Bionics told the SEC that its initial public offering and a concurrent private placement brought in gross proceeds of $229.1 million before underwriting discounts and expenses. The company's own release puts its share of the IPO at about $212.1 million, well below the $234.6 million headline figure.
BBNXThe company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report.
PYPDNeogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier.
NEOGIntellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure.
NTLAThe supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024.
CELCBellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings.
OSRH
aibio